

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268

Status	RECRUITING
Phase	Phase 3
Sponsor	Pfizer
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (7)

- No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.
- Disease Characteristics:
- Participants who meet all of the following AD criteria:
 - A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
 - A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA e10%, vIGA e3, EASI e16, and WI-NRS e4); and
- ... and 2 more (see full listing online)

Exclusion (25)

- Participants are excluded from the study if any of the following criteria apply:
- Medical Conditions:
 - Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
 - If the participant has SDQ total score e17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
 - Have any of the following medical conditions:
- ... and 20 more (see full listing online)

Locations (39 total)

Cahaba Dermatology & Skin Health Center, LLC, Birmingham, Alabama, United States
Arkansas Research Trials, North Little Rock, Arkansas, United States
Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego, California, United States
... and 36 more locations